GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of GSK (LON:GSK) in a research report report published on Wednesday,Digital Look reports. They currently have a GBX 2,000 price target on the stock.

GSK has been the subject of several other reports. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th. Citigroup reduced their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,048.57.

GSK Trading Down 0.1%

Shares of GSK stock opened at GBX 1,918.50 on Wednesday. GSK has a fifty-two week low of GBX 1,440.29 and a fifty-two week high of GBX 2,282. The stock has a market cap of £76.85 billion, a P/E ratio of 16.29, a P/E/G ratio of 1.24 and a beta of 0.29. The business has a fifty day simple moving average of GBX 1,936.82 and a 200-day simple moving average of GBX 1,998.90. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jonathan Symonds acquired 1,550 shares of the business’s stock in a transaction dated Friday, June 19th. The stock was acquired at an average price of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Vishal Sikka acquired 1,266 shares of GSK stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. Insiders have bought 3,618 shares of company stock valued at $13,481,942 in the last ninety days. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.